Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity

Area of Science:

• Pulmonology
• Allergy Immunology
• Medical Mycology

Background:

• Inhalation of Aspergillus spores can trigger various respiratory conditions in susceptible individuals.
• These include Aspergillus-induced asthma, allergic bronchopulmonary aspergillosis (ABPA), and allergic Aspergillus sinusitis (AAS).
• ABPA is an immunologically mediated disease primarily affecting asthma and cystic fibrosis (CF) patients.

Purpose of the Study:

• To review the diagnostic criteria and management strategies for ABPA and AAS.
• To highlight the role of imaging and serological markers in diagnosis.
• To discuss the co-existence and management of these conditions, including aspergilloma.

Main Methods:

• Review of diagnostic criteria for ABPA and AAS.
• Emphasis on the role of imaging (e.g., bronchiectasis) and serological tests (IgE, IgG).
• Discussion of clinical presentation, histopathology, and management.

Main Results:

• Central bronchiectasis with normal tapering bronchi is pathognomonic for ABPA in non-CF patients.
• Elevated serum IgE and Aspergillus-specific IgE/IgG are crucial for diagnosis.
• Mucoid impaction in paranasal sinuses is characteristic of AAS, with fungal elements as a hallmark.
• Co-existence of ABPA and AAS is uncommon despite similar histopathology.
• Aspergilloma formation can occur in cavitary ABPA, increasing disease severity.

Conclusions:

• Diagnosis of ABPA and AAS requires specific criteria, with imaging and serology playing key roles.
• Oral corticosteroids are the primary treatment for allergic aspergillosis.
• Antifungal agents are adjunctive in ABPA to reduce fungal load.
• Screening for ABPA in Aspergillus-sensitized asthma patients and evaluation for AAS are recommended.
• Concurrent ABPA, AAS, and aspergilloma have been documented, necessitating comprehensive patient assessment.